Strides Pharma Science Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 7 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹8.9K Cr
Strides aims to grow its U.S. The company reported a phenomenal year in FY '25 with highest ever PAT on an operating basis.
From Strides Pharma Science Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹986
Market Cap
₹8.9K Cr
P/E Ratio
15.4
How does Strides Pharma Science Ltd rank in Pharmaceuticals & Biotechnology?
Compare Strides Pharma Science Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Strides Pharma Science Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.3K Cr, net profit ₹129 Cr.
Full financials →📊 Revenue & Sales Performance
- →Strides aims to grow its U.S. business from $291 million to $400 million in revenue, focusing on measured product launches rather than rapid acceleration.
- →Out of a 60-product library identified for re-launch in the U.S., not all will be launched; launches are carefully timed to control growth sustainably.
- →Average revenue per product launch has increased from about $3 million three years ago to $5 million currently, with several products exceeding $20 million.
- →Beyond the $400 million U.S. target, new growth will be driven by internal R&D, including 505(b)(2) filings expected at 3-4 products per year.
- →Other regulated markets are expected to mirror U.S. growth and could reach size parity within 4-5 years, driven by portfolio expansion and new customer acquisitions.
- →Growth markets show strong growth (>24%), while access markets are expected to improve with new pilot programs.
- →No significant pricing pressure expected; underperforming products are exited to maintain profitability.
📈 Profitability & Margins
- →The company reported a phenomenal year in FY '25 with highest ever PAT on an operating basis.
- →Operational EPS for the year grew 12x to INR37.46 per share; quarterly EPS ended at INR12.27 per share.
- →EBITDA margin improved, achieving 18.3% in Q4 and close to 20% expected within 3 years.
- →Management aims to maintain consistent quarter-on-quarter EBITDA growth, having achieved this for 12+ quarters.
- →Focus remains on opex leverage, higher EBITDA growth, and absolute gross margin expansion.
- →No indication of a growth holiday; EBITDA and PAT expected to grow significantly faster than revenue.
- →Expected to sustain high teens to ~20% EBITDA margins in next 3 years.
- →Free cash generation expected to remain strong, supporting debt reduction and R&D investments.
- →Overall, high confidence in steady earnings and profitability growth over medium term.
🏗️ Capital Expenditure Plans
- →Recent capex of INR350 crores over the last 2 years focused on debottlenecking and increasing capacities.
- →For FY '26, capex expected to be much lower than INR245 crores spent in the previous year.
- →Future capital allocation is shifting towards increased R&D spend, especially for the Beyond $400 million U.S. portfolio.
- →R&D spend is almost doubling, with about $15 million of the $20 million targeted for beyond $400 million strategy.
- →No plans for major new capex; focus on measured launches and technology-driven capacity enhancements.
- →Retaining strategic investments like OneSource (held in subsidiary Arco Lab) for potential use but no current plans to exit.
- →Emphasis on efficient use of existing capacity and automation rather than large-scale new capital investments.
💰 Fundraising & Capital Structure
- →There is no mention of any current or planned new fundraising through debt or equity.
- →The company has significantly reduced its gross debt from INR3,000 crores to INR1,500 crores and is comfortable with its current debt position.
- →Debt reduction is targeted at INR300-500 crores per year over the next few years, aiming to reduce another INR1,000 crores in 2 to 2.5 years.
- →The company prefers to maintain a strong balance sheet and does not plan to be debt-free but within a comfortable debt range.
- →Funding of growth and R&D initiatives will be through internal cash generation without new investments.
- →No guidance or indication exists on raising equity capital; focus remains on operational cash flows for funding.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Strides Pharma Science Ltd Q4 FY25 results?
Strides aims to grow its U.S. The company reported a phenomenal year in FY '25 with highest ever PAT on an operating basis.
What is Strides Pharma Science Ltd share price analysis?
Strides Pharma Science Ltd currently shows a neutral. The stock trades at a P/E of 15.4 with a market cap of ₹8,944 Cr. Investors should review the full earnings analysis for detailed insights.
Is Strides Pharma Science Ltd planning capital expenditure?
Recent capex of INR350 crores over the last 2 years focused on debottlenecking and increasing capacities. - For FY '26, capex expected to be much lower than INR245 crores spent in the previous year. - Future capital allocation is shifting towards increased R&D spend, especially for the Beyond $400 million U.S.
Keep Strides Pharma Science Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.